Clinical trials: Esophagogastric Junction Disorder
Esophageal Cancer
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00381706
- Testing
- cetuximab, ECF, IC
- Where
- 227 sites in United States
- Volunteers
- 245 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Esophagus Squamous Cell Carcinoma
Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction
This is a prospective, multicenter, exploratory study. Patients with advanced esophageal or gastro-esophageal junction squamous carcinoma who had progressed on first-line chemotherapy combined with immune checkpoint inhibitors…
- Trial name
- NCT05865132
- Testing
- Palbociclib, Afatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- AIPING ZHOU
Advanced Malignancies
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
- Trial name
- NCT03241173
- Testing
- INCAGN01949, Nivolumab, Ipilimumab
- Where
- 15 sites in United States
- Volunteers
- 52 people
- Sponsor
- Incyte Biosciences International Sàrl
Gastric Cancer
A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer
This study will evaluate the disease free survival rate of a combination of capecitabine [Xeloda] and oxaliplatin (XELOX) with trastuzumab [Herceptin] in patients with resectable gastric cancer.
- Trial name
- NCT01130337
- Testing
- Capecitabine [Xeloda], Oxaliplatin, Trastuzumab [Herceptin]
- Where
- 30 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer, Gastric Cancer
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination to treat metastatic esophageal and gastric cancer in an effort to see what effects (good and bad) the combination may have on the…
- Conditions
- Esophageal Cancer, Gastric Cancer, GE Junction Cancer
- Trial name
- NCT00165464
- Testing
- Taxotere, Cisplatin, Irinotecan
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Solid Tumor, Gastric Cancer
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05156866
- Testing
- TORL-2-307-ADC
- Where
- 12 sites in United States, South Korea
- Volunteers
- 163 people
- Sponsor
- TORL Biotherapeutics, LLC
Locally Advanced or Metastatic Malignant Solid Tumors
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1.
- Trial name
- NCT04225117
- Testing
- enfortumab vedotin, pembrolizumab
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 329 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Gastric Neoplasm
Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression
Efficacy and safety of fruquintinib in combination with sintilizumab and SBRT in the treatment of oligonadenocarcinoma progression in the stomach or gastroesophageal junction
- Trial name
- NCT06977061
- Testing
- Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy
- Volunteers
- 30 people
- Sponsor
- Queling Liu
Gastric Cancer (GC)
A Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Refractory to ≥ Second-Line Chemotherapy
This study aims to evaluate the efficacy and safety of TAS-102 combined with nedaplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma who have experienced disease progression after two or more…
- Trial name
- NCT07913165
- Testing
- TAS102+Nedaplatin
- Volunteers
- 36 people
- Sponsor
- Tao Zhang
Gastric Cancer, Peritoneal Metastases
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
To evaluate the efficacy and safety of Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion as First-line Treatment for advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma…
- Conditions
- Gastric Cancer, Peritoneal Metastases, Ascites, Malignant
- Trial name
- NCT06046963
- Testing
- Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion, Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhejiang Cancer Hospital
Oesophageal Cancer, Gastro-Oesophageal Junction Cancer
A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer
SOlar is a multi-centre phase II clinical trial of single agent olaparib in advanced oesophagogastric cancer.
- Conditions
- Oesophageal Cancer, Gastro-Oesophageal Junction Cancer, Gastric Cancer
- Trial name
- SOLAR (NCT03829345)
- Testing
- Olaparib
- Where
- 2 sites in United Kingdom
- Volunteers
- 54 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Gastric Cancer
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
This is a prospective, single-center, randomized controlled, phase II clinical trial. The study aims to enroll 48 patients with resectable, locally advanced gastroesophageal junction adenocarcinoma who have not received any…
- Trial name
- NCT07277439
- Testing
- Radiochemoimmunotherapy, Immunomodulation
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric Cancer
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
Recently, a number of clinical studies were carried out to evaluate the therapeutic effects of PD-1 antibodies combined with chemotherapy as preoperative neoadjuvant therapy of gastric cancer (GC) worldwide.
- Trial name
- NCT05594381
- Testing
- Sintilimab
- Volunteers
- 90 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
This is an open label, single-arm phase II, multi-institutional trial to evaluate the efficacy and safety of the combination of nab-paclitaxel and FOLFOX (FOLFOX-A) as first line therapy for patients diagnosed with…
- Trial name
- NCT03283761
- Testing
- Nab-paclitaxel 150 mg/m^2, Oxaliplatin 85 mg/m^2, 5-FU 1200 mg/m^2 x 2 D
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Al B. Benson, III, MD
Esophageal Cancer, Gastric Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether combining chemotherapy with surgery is more effective than surgery alone.
- Trial name
- NCT00002883
- Testing
- cisplatin, fluorouracil, adjuvant therapy
- Where
- France
- Volunteers
- 250 people
- Sponsor
- UNICANCER
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma…
- Trial name
- NCT04704934
- Testing
- Trastuzumab deruxtecan, Ramucirumab, Paclitaxel
- Where
- 156 sites in Argentina, Belgium and 22 more
- Volunteers
- 490 people
- Sponsor
- Daiichi Sankyo
Gastric Cancer
A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer
The purpose of this observational study is to assess the effectiveness and safety of nivolumab in participants with previously untreated advanced or metastatic Gastric Cancer (GC), Gastro-oesophageal Junction (GEJ)…
- Trial name
- INGA (NCT05165264)
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- Bristol-Myers Squibb
Stomach Neoplasms, Esophageal Neoplasms
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to assess objective tumor response in the single agent treatment of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
- Trial name
- NCT00813072
- Testing
- PEP02, irinotecan, docetaxel
- Where
- 22 sites in Bosnia and Herzegovina, Croatia and 4 more
- Volunteers
- 135 people
- Sponsor
- PharmaEngine
Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer
Validation of a Nutrition Screening Tool
The objective of this study is to evaluate the sensitivity and specificity of two nutrition screening tools to identify inpatients with malnutrition or at risk of malnutrition.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer, Endometrial Cancer, Esophageal Cancer
- Trial name
- NCT01851928
- Where
- United Kingdom
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Gastric Cancer
Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
Previously untreated patients with limited metastatic stage (see protocol for details on criteria) will receive 4 cycles of FLOT (5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel).
- Trial name
- FLOT5 (NCT02578368)
- Testing
- 5-Fluorouracil, Leucovorin, Oxaliplatin
- Where
- Germany
- Volunteers
- 183 people
- Sponsor
- Krankenhaus Nordwest